Document Detail


Temporal ordering of caspase activation and substrate cleavage during antigen receptor-triggered apoptosis in Ramos-Burkitt lymphoma B cells.
MedLine Citation:
PMID:  12851674     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We demonstrate here that selective activation of endogenous members of the caspase family and cleavage of substrates responsible for the maintenance of nuclear functional and structural integrity are major effectors of antigen receptor (AgR)- and ionomycin-triggered apoptosis in Ramos-Burkitt lymphoma (Ramos-BL) B cells. Ramos-BL B cells express significant proenzyme levels of caspase-2, -3, -7 and -8, low levels of caspase-6 and are caspase-1-negative. However, while anti-IgM and ionomycin trigger for significant activation of caspase-3, -7 and -8 at 12-16 h and at 4 h post-stimulation respectively, both anti-IgM and ionomycin fail to activate caspase-2 indicating that AgR- and ionomycin-triggered Ramos-BL B cell apoptosis is mediated by the selective activation of, at least, caspase-3, -7 and -8. Anti-IgM triggers for cleavage of the resident nuclear proteins poly(ADP-ribose) polymerase (PARP) at 8 h, lamins B1 and B2 from 12 to 16 h; likewise, ionomycin triggers for degradation of PARP at 2 h, lamins B1 and B2 at 4 h. Signal transduction through CD40 rescues Ramos-BL B cells from AgR- and ionomycin-triggered apoptosis at a very early stage of the apoptotic process by inhibiting both the early cleavage of PARP as well as the activation of caspase-3, -7 and -8 and cleavage of lamin B1; CD40-mediated rescue occurs upstream of CD40-induced expression of Bcl-2 and increased expression of Bcl-xL. In such cellular populations subject to regulation through apoptosis, dysregulation of the apoptotic mechanisms can have devastating consequences by contributing to the pathogenesis of malignancy as well as to lymphoproliferative and autoantibody disorders. An understanding of the role played by caspases in the execution of apoptosis may provide insight into the pathogenesis of these disease states and thereby provide targets for novel therapeutic strategy.
Authors:
Sungkwan An; In-Chul Park; Chang Hun Rhee; Seok-Il Hong; Kirstine Knox
Related Documents :
17442474 - Norcantharidin preferentially induces apoptosis in human leukemic jurkat cells without ...
16162654 - Changes in intracellular electrolyte concentrations during apoptosis induced by uv irra...
18758954 - Parp and cell death or protection in rat primary astroglial cell cultures under lps/ifn...
21274634 - The role of iap antagonist proteins in the core apoptosis pathway of the mosquito disea...
10803324 - Review: the application of dendritic cell-derived exosomes in tumour immunotherapy.
9317104 - Fas- and fasl-deficient mice are resistant to induction of autoimmune encephalomyelitis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of oncology     Volume:  23     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-07-09     Completed Date:  2004-03-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  257-68     Citation Subset:  IM    
Affiliation:
Department of Biochemistry, University of Oxford, UK. genomicslab@hanmail.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD40 / immunology,  metabolism*
Apoptosis / drug effects*,  physiology
B-Lymphocytes / cytology*,  immunology,  metabolism
Burkitt Lymphoma / metabolism*,  pathology
Caspase 1
Caspases / metabolism*
Cell Cycle / drug effects
Child
Enzyme Activation
Enzyme Inhibitors / pharmacology
Enzyme Precursors / metabolism
HL-60 Cells
Humans
Immunoglobulin M / pharmacology
Ionomycin / pharmacology
Ionophores / pharmacology
Jurkat Cells
Lamin Type B / metabolism
Male
Poly(ADP-ribose) Polymerases / metabolism
Proto-Oncogene Proteins c-bcl-2 / metabolism
Receptors, Antigen, B-Cell / metabolism*
bcl-X Protein
Chemical
Reg. No./Substance:
0/Antigens, CD40; 0/BCL2L1 protein, human; 0/Enzyme Inhibitors; 0/Enzyme Precursors; 0/Immunoglobulin M; 0/Ionophores; 0/Lamin Type B; 0/Proto-Oncogene Proteins c-bcl-2; 0/Receptors, Antigen, B-Cell; 0/bcl-X Protein; 0/lamin B1; 0/lamin B2; 56092-81-0/Ionomycin; EC 2.4.2.30/Poly(ADP-ribose) Polymerases; EC 3.4.22.-/Caspases; EC 3.4.22.36/Caspase 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of fetal Doppler in obstetrics.
Next Document:  The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor p...